Major cardiovascular adverse events in Fabry disease patients receiving agalsidase alfa.
Cardiovascular mortality (CVM) has become the major contributor to overall Fabry disease (FD) mortality in the enzyme replacement therapy (ERT) era. Our objectives were to describe causes an...